DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

All news

Neutral impactResults

Nath Bio-Genes (India) Limited — Outcome of Board Meeting

NSE 2 hrs ago·29 Jul 2026, 10:50 am

Company NSE

Nath Bio-Genes (India) Limited has informed stock exchanges that its board has approved the financial results for the period ending June 30, 2026. This filing is a standard corporate disclosure required for public companies to keep investors updated on their financial performance.

For investors, this news confirms that the company has completed its internal review and reporting processes. While the specific figures have not yet been disclosed, the mere fact of the filing suggests the board has reviewed the accounts and is ready to present them to the market.

Investors should watch for the official release of the financial statements. The key focus will be on the company's revenue growth, net profit margins, and any commentary regarding future business outlook or debt levels.